Overview
- The US has officially imposed a 27% reciprocal tariff on Indian goods, effective April 2, 2025, escalating trade tensions between the two nations.
- India is carefully examining the implications of the new tariffs and consulting stakeholders, including industries and exporters, to gauge their impact.
- While India's pharmaceutical sector, which exported over $8 billion to the US in 2024, is exempt from the tariffs, other sectors face significant challenges.
- Bilateral trade negotiations are ongoing, with India proposing tariff reductions and focusing on deepening supply chain integration and technology transfers.
- Both nations reaffirm their commitment to the Comprehensive Global Strategic Partnership, aiming to double bilateral trade to $500 billion by 2030.